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a  b  s  t  r  a  c  t
Muntingia  calabura  L., Muntingiaceae,  is a medicinal  plant  for various  pain-related  diseases.  The aims  of
the present  study  were  to determine  the antinociceptive  proﬁle  and  to elucidate  the  possible  mech-
anisms  of antinociception  of petroleum  ether  partition  obtained  from  crude  methanol  extract  of  M.
calabura  leaves  using  various  animal  models.  The  antinociceptive  proﬁle  of petroleum  ether  fraction
(given  oral;  100,  250 and  500  mg/kg)  was  established  using  the in  vivo  chemicals  (acetic  acid-induced
abdominal  constriction  and  formalin-induced  paw  licking  test)  and  thermal  (hot  plate  test)  models
of  nociception.  The  role  of glutamate,  TRPV1  receptor,  bradykinin,  protein  kinase  C, potassium  chan-
nels,  and  various  opioid  and  non-opioid  receptors  in  modulating  the  partition’s  antinociceptive  activity
was  also  determined.  The  results  obtained  demonstrated  that  petroleum  ether  partition  exerted  signif-
icant  (p  < 0.05)  antinociception  in all the  chemicals-,  thermal-,  capsaicin-,  glutamate-,  bradykinin,  and
phorbol  12-myristate  13-acetate  (PMA)-induced  nociception  models.  The  antinociceptive  activity  was
reversed following  pretreatment  with  opioid  antagonists  (i.e.  naloxone,  -funaltrexamine,  naltrindole
and  nor-binaltorphimine),  and  the  non-opioid  receptor  antagonists  (i.e. pindolol  (a -adrenoceptor),
haloperidol  (a  non-selective  dopaminergic),  atropine  (a non-selective  cholinergic  receptor),  caffeine  (a
non-selective  adenosinergic  receptor),  and  yohimbine  (an  2-noradrenergic)).  In addition,  pretreatment
with  l-arginine  (a  nitric  oxide  (NO)  donor),  NG-nitro-l-arginine  methyl  esters  (l-NAME;  an  inhibitor  of
NO  synthase  (NOS)),  methylene  blue  (MB;  an  inhibitor  of  cyclic-guanosine  monophosphate  (cGMP)  path-
way),  or  their  combination  failed  to inhibit  petroleum  ether  partition’s  antinociception.  In  conclusion,
petroleum  ether  partition  exerts  antinociceptive  activity  at the peripheral  and  central  levels  via the  mod-
ulation  of,  partly,  the opioid  (i.e. ,  and  ) and  several  non-opioids  (i.e. -adrenergic,  dopaminergic,
cholinergic,  adenosinergic,  and  2-noradrenergic)  receptors,  glutamatergic,  TRPV1  receptors,  PKC  and
K+ channels  systems,  but not  l-arg/NO/cGMP  pathway.
© 2016  Sociedade  Brasileira  de  Farmacognosia.  Published  by  Elsevier  Editora  Ltda.  This  is an  open
he CCaccess  article  under  t
ntroduction
Various neurotransmitters and receptor systems take part in
he modulation of pain processes in the central nervous system
CNS) and peripheral nervous system (PNS), such as the vanilloid
Cui et al., 2006), opioid (Craig and Sorkin, 2011), glutamate
Osikowicz et al., 2013), protein kinase C (PKC; Velázquez et al.,
007), potassium ion (K+) channels (Ocana et al., 2004), and nitric
xide/cyclic guanosine monophosphate (NO/cGMP) pathways
∗ Corresponding author.
E-mail: zaz@upm.edu.my (Z.A. Zakaria).
http://dx.doi.org/10.1016/j.bjp.2015.12.007
102-695X/© 2016 Sociedade Brasileira de Farmacognosia. Published by Elsevier Edit
reativecommons.org/licenses/by-nc-nd/4.0/). BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
(Schmidtko et al., 2009). Despite the rapid advancements in the
development of various treatments for pain, the clinical efﬁcacy
and tolerability of conventional analgesics can be overshadowed
by its unwanted adverse effects. Some patients have taken alterna-
tive approach to treat pain, including complementary alternative
medicine (CAM) in order to avoid these side effects (Astin, 1998).
The use of natural product as alternative therapies is an increas-
ingly popular method to treat such discomfort, either alone or as
a complement to conventional medical approaches (Wirth et al.,
2005). Holt and Chandra (2002) categorized natural products as
herbs, herbal concoctions, traditional Chinese medicines, dietary
supplements and alternative medicines. The research in natu-
ral product based on its ethnopharmacological knowledge has
ora Ltda. This is an open access article under the CC BY-NC-ND license (http://
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rovided substantial contributions to drug innovation through
he discovery of novel chemical structure and/or mechanism
f actions (Rates, 2001). Muntingia calabura L., Muntingiaceae,
he sole species in the genus, has been traditionally used in
he Southeast Asia and tropical America (Kaneda et al., 1991;
shimo et al., 1993) to treat headaches and gastric ulcer, and
s an emmenogogue, antidyspeptic, antispasmodic, diaphoretic,
ranquillizer and tonic (Kaneda et al., 1991; Perez-Arbelaez, 1975).
arious medicinal properties have been scientiﬁcally reported
rom M.  calabura leaves, including anti-tumor (Kaneda et al.,
991; Su et al., 2003), hypotensive (Shih et al., 2006), antibacterial
Zakaria et al., 2006a,b; Zakaria et al., 2010; Suﬁan et al., 2013;
snarianti et al., 2013), antiplatelet aggregation (Chen et al., 2007),
nti-inﬂammatory, antipyretic and antinociceptive (Zakaria et al.,
007a,b), anti-myocardial infarction (Nivethetha et al., 2009),
ntihypertensive (Shih, 2009), antioxidant (Siddiqua et al., 2010;
akaria et al., 2011; Aruna Sindhe et al., 2013) cytotoxic (Chen
t al., 2005; Suﬁan et al., 2013), antiproliferative (Zakaria et al.,
011), antihyperglycemic (Aruna Sindhe et al., 2013), antiulcer
Balan et al., 2014; Zakaria et al., 2014a,b), and hepatoprotective
Mahmood et al., 2014) activities. Other parts of M. calabura
ave also been reported to exert insecticidal (Neto Bandeira
t al., 2013), anti-inﬂammatory (Preethi et al., 2012; Gomathi
t al., 2013), antioxidant (Preethi et al., 2010; Gomathi et al.,
013) activities. With regards to the antinociceptive studies,
he methanol extract of M.  calabura has been reported to show
ntinociceptive activity (Mohd Sani et al., 2012), which was
ater shown to involve activation of the non-selective opioid
i.e. -, - and -opioid) and non-opioid (i.e.  adenosinergic,
2-noradrenergic, and -adrenergic) receptors, modulation of
he ATP-sensitive K+ channel, and inhibition of bradikinin and
rotein kinase C actions (Zakaria et al., 2014a,b). Moreover, the
uthors also suggested that the observed antinociceptive activities
nd its mechanism of actions were resulted from the synergistic
ffect of the bioactive compounds, ﬂavonoids, saponins, tannins
nd steroids, possessed by the plant extracts. Recent laboratory
esearch proved that the crude methanol extract of M. calabura
MEMC) leaves possesses good therapeutic effect in reducing noci-
eptive response (Mohd Sani et al., 2012; Zakaria et al., 2014a,b)
nd further study by Mohamad Yusof et al. (2013) leads to the
solation of four ﬂavonoid-based antinociceptive-bearing bioactive
ompounds, of which one is a new compound called calaburone (8-
ydroxy-6-methoxyﬂavone) and three were known compounds,
amely 5-hydroxy-3,7,8-trimethoxyﬂavone,3,7-dimethoxy-5-
ydroﬂavone and 2′,4′-dihydroxy-3′-methoxychalcone. In this
tudy, we further evaluate the possible antinociceptive activity
nd its mechanism of action of the petroleum ether partition
xtracted from MEMC.
aterials and methods
lant collection
The leaves of Muntingia calabura L., Muntingiaceae, were col-
ected from its natural habitat in Shah Alam, Selangor, Malaysia.
lant identiﬁcation has been made earlier (Balan et al., 2014) and
 voucher specimen (SK 964/04) has been deposited at the Herbar-
um of Institute of Biosciences, Universiti Putra Malaysia, Serdang,
elangor, Malaysia.
reparation of methanol extract of M.  calabura (MEMC) and
ts petroleum ether fraction (PEMC)
The method for preparation of MEMC  was described in detail
y Balan et al. (2014). The obtained MEMC  was  then extractedarmacognosia 26 (2016) 408–419 409
subsequently with petroleum ether using the method described
in detail by Mohamad Yusof et al. (2013). MEMC (2 g) dis-
solved in a solvent with a ratio of 1:7:2 which consist of MeOH
(100 ml), petroleum ether (700 ml)  and distilled water (200 ml).
The mixture was  rigorously shaken using a separatory funnel and
then left to separate. The supernatant was  collected and ﬁltered
while the residue was  soaked again with petroleum ether until
the supernatant become colorless. The collected petroleum ether
supernatant was also subjected to rotary evaporator at 40 ◦C under
reduced pressure to obtain a concentrated extract of petroleum
ether of M. calabura (PEMC).
Experimental animals
Male ICR mice (25–30 g) and Sprague Dawley rat (150–180 g)
were obtained from a private supplier (Chenur Supplier, Selan-
gor, Malaysia) and acclimatized for three days in the Animal
Holding Unit, Faculty of Medicine and Health Sciences, UPM.
Details on the handled and cared of these animals have been
described by Balan et al. (2014) and was in compliance with
current UPM guidelines for the care of laboratory animals (Ethi-
cal approval no.: UPM/FPSK/PADS/BR-UUH/00404) and the ethical
guidelines for investigations of experimental pain in conscious ani-
mals (Zimmermann, 1983). All experiments (n = 6) were conducted
between 09:00 and 16:00 h to minimize the effect of environmental
changes.
Drugs and chemicals
Capsaicin, glutamate, naloxone, -funaltrexamine, naltrindole,
nor-binaltorphimine, apamin, charybdotoxin, tetraethylammon-
ium, atropine, haloperidol, pindolol, yohimbine, caffeine, gliben-
clamide were purchased from Sigma–Aldrich (USA) while
bradykinin was purchased from Tocris Bioscience, UK. They were
prepared at the desired dose by dissolving them in distilled water
(dH2O). Acetyl salicylic acid (ASA), morphine and capsezepine
(Sigma–Aldrich, USA) were dissolved in 10% DMSO while phorbol
12-myristate 13-acetate (PMA; Sigma–Aldrich, USA) was  dis-
solved in PBS solution. Acetic acid, petroleum ether, methanol
and dimethyl sulfoxide (DMSO) were purchased from Fisher Sci-
entiﬁc (U.K.). All drugs and PEMC were given in a 10 ml/kg
basis.
Antinociceptive analysis
Acetic acid-induced abdominal constriction test
The acetic acid-induced abdominal constriction was  carried out
with slight modiﬁcations according to the method described in
detail by Mohd Sani et al. (2012). The mice were pretreated orally
with 10% DMSO (vehicle, negative control), 100 mg/kg ASA (posi-
tive control) or PEMC (100, 250 and 500 mg/kg) and 60 min  later
subjected to the abdominal constriction test.
Hot plate test
The hot-plate test, used to assess the central antinociceptive
activity of PEMC, was performed according to the method described
in detail by Mohd Sani et al. (2012). The mice were pretreated orally
with vehicle (10% DMSO, negative control), 5 mg/kg morphine (pos-
itive control) or PEMC (100, 250 and 500 mg/kg) 60 min prior to
subjection to the hot plate test.
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ormalin test
The formalin test was carried out as described in detail in previ-
us research by Mohd Sani et al. (2012). Rats were administered
rally with the test solutions (i.e.  10% DMSO (negative control),
00 mg/kg ASA (peripherally acting positive control), 5 mg/kg mor-
hine (centrally acting positive control) or PEMC (100, 250 and
00 mg/kg)) 60 min  prior to the formalin injection. The nocicep-
ive response described as the early phase and the late phase was
ecorded at the respective 0–5 min  and 15–30 min  following the
ormalin administration.
etermination of the motor coordination and sedative
ffects of PEMC
ffect of PEMC on motor coordination
ota-rod test
A rota-rod tread mill device (Ugo Basil, Italy) was  employed
o assess the effect of PEMC on motor coordination (Melo et al.,
011) with slight modiﬁcations. In the beginning, mice capable
f remaining on the rota-rod apparatus longer than 210 s (9 rpm)
ere selected 12 and 24 h prior to the test. Thirty minutes after the
dministration of either 10% DMSO (negative control), diazepam
2.5 mg/kg, i.p.)  or PECM (100, 250 and 500 mg/kg, p.o.), each
ouse was tested on the rota-rod apparatus at 0.5, 1 and 2 h post-
reatment. The time (s) the mice were able to remain on top of
he bar was recorded for up to 210 s. Decrease in fall off time is
uggestive of depression of the central nervous system (CNS).
edative effect of PEMC
odium pentobarbital-induced sleeping time test
The sedative effect of PEMC in combination with sodium pen-
obarbital (SP) was evaluated (Martínez-Vázquez et al., 2012). For
his purpose, a total of 30 mice were divided into ﬁve groups (n = 6)
nd orally administered with either 10% DMSO (negative control),
iazepam (2.5 mg/kg, i.p.)  or PECM (100, 250 and 500 mg/kg, p.o.)
0 min  before the intraperitoneal administration of sodium pento-
arbital (42 mg/kg, i.p.). Each mouse was placed on a warm table
nd cautiously monitored for the onset of uncoordinated move-
ents subsequent to the sedative phase of the test. Loss of the
ighting reﬂex related to the hypnosis phase and the duration of
leep were also observed. The effects were recorded as follows:
ime passed between the administrations of pentobarbital until loss
f righting reﬂex was recorded as of the onset of sleep, whilst the
ime from the loss to recovery was considered as the duration of
leep.
nvestigation on the possible mechanisms of antinociception of
EMC
apsaicin-induced paw licking test
Antinociceptive action of PEMC on vanilloid receptors (TRPV1)
ere investigated using the procedure described by Goncalves
t al. (2005) with slight modiﬁcations. Rats were pretreated orally
ith vehicle, capsazepine (0.17 mmol/kg) or PEMC (100, 250 and
00 mg/kg) 60 min  before capsaicin injection (1.6 g/paw, 50 l)
nto the i.pl. region of the rat’s right hind paw. The induced rat
ndividually observed in a transparent glass chamber for 5 min, and
he amount of time the animals spent licking the injected paw was
ecorded with a chronometer.lutamate-induced paw licking test
A slight modiﬁcation from the procedure described by Beirith
t al. (2002) was  used to study the role of glutamatergic systemarmacognosia 26 (2016) 408–419
in the modulation of PEMC antinociceptive action. Rats were pre-
treated orally with vehicle, ASA (100 mg/kg) or PEMC (100, 250 and
500 mg/kg) 60 min  prior to glutamate injection. A volume of 50 l
of glutamate (10 mol/paw) was injected into the i.pl. region on
the right hind paw of each rat. Immediately after the phlogistic
agent administration, the induced rat were placed in a transparent
glass cage observation chamber and individually observed from 0
to 15 min. The amount of time the animals spent licking or biting
the injected paw was recorded with a chronometer.
Involvement of protein kinase C
The experiment was  conducted based on the previously
described method by Savegnago et al. (2007). A volume of 50 l
of PMA  (a protein kinase C activator) solution (0.05 g/paw) was
injected into the ventral surface of the right hind paw of the rat
60 min  after the oral administration of vehicle, ASA (100 mg/kg) or
PEMC (100, 250 and 500 mg/kg). The animals were observed indi-
vidually from minute 15 to 45 following PMA  injection and the
amount of time the rat spent licking the injected paw was recorded
using a chronometer.
Bradykinin-induced nociception
Based on the method previously described by Ferreira et al.
(2004), bradykinin (10 nmol/paw in 50 l) was  injected into the
intraplantar surface of the right hind paw of each rat 60 min  after
the oral administration of vehicle, ASA (100 mg/kg) or PEMC (100,
250 and 500 mg/kg). The bradykinin-induced rat was  observed
individually for 10 min, and the amount of time they spent licking
the injected paw was recorded.
Involvement of l-arginine/nitric oxide/cyclic guanosine
monophosphate pathway
To determine the role of nitric oxide/cyclic-guanosine
monophosphate (NO/cGMP) pathway in the modulation of
PEMC antinociceptive activity the method described in detail by
Zakaria et al. (2006a,b) was  adopted. Mice were pretreated with
20 mg/kg l-arginine, l-NAME, MB  or their respective combination
(l-arginine with l-NAME or l-arginine with MB)  followed 5 min
later by pretreatment with vehicle or PEMC (500 mg/kg), respec-
tively. Sixty minutes after the administration of test solutions, the
mice were subjected to the abdominal constriction test.
Involvement of potassium channels
To determine the effect of PEMC-induced antinociception on
K+ channels, a method previously described by Alves and Duarte
(2002) was  used. Rats were pre-treated with glibenclamide (an
ATP sensitive K+ channel inhibitor; 10 mg/kg, i.p.), apamin (small
conductance Ca2+-activated K+ channels, 0.04 mg/kg, i.p.),  charyb-
dotoxin (an inhibitor of large conductance Ca2+-activated K+
channels, 0.02 mg/kg, i.p.) and tetraethylammonium chloride (a
non-selective voltage dependant K+ channel inhibitor, 4 mg/kg,
i.p.) 15 min  before oral administration of either vehicle or PEMC
(500 mg/kg). Sixty minutes later, pain was  induced using 0.6% acetic
acid. The number of writhing will be recorded for 25 min, 5 min
following acetic acid injection.
Effect of various receptor antagonists on PEMC-induced
antinociceptionThe detail method described by Zakaria et al. (2014a,b) was
adopted to study the effect of various receptor antagonist on
the antinociceptive activity of PEMC. Groups of animal were
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Fig. 1. Number of abdominal constrictions in mice during the acetic acid-induced
abdominal constriction test after treatment with PEMC, acetylsalicylic acid (ASA;
positive control), or vehicle ([C] negative control). Acetic acid was administered
intraperitoneally 60 min  before oral administration of treatment. n = 6 in each group.
Numbers above the bars indicate the percentage of analgesia. ***p < 0.001 as com-
in time that the animals stayed on the rota-rod apparatus compared
to the control group (Table 1).
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Fig. 2. Effect of PEMC in formalin-induced paw licking test. Data represents the
mean ± SEM of six rats. The rats were pretreated with vehicle (10% DMSO), PEMCZ.A. Zakaria et al. / Revista Brasileir
re-treated with caffeine (3 mg/kg, i.p.),  atropine (10 mg/kg, i.p.),
aloperidol (20 mg/kg, i.p.), pindolol (1 mg/kg. i.p.), or yohimbine
0.15 mg/kg, i.p)  15 min  before the oral administration of vehicle or
EMC (500 mg/kg). Sixty minutes later after the administration of
EMC or vehicle, the mice were subjected to the abdominal con-
triction test.
nalysis of opioid receptor subtypes
Evaluation on the involvement of opioid receptor subtype was
one using the abdominal constriction test which is similar with
reviously described. The preparation of the opioid antagonists’
oses and timing of administration were based on previously con-
ucted studies by Choi et al. (2003), Reeta et al. (2006) and Zakaria
t al. (2014a,b). The  opioid antagonist, -funaltraxamine (-FNA;
0 mg/kg, i.p.),  opioid receptor antagonist, naltrindole (NALT;
 mg/kg. i.p.)  or  opioid receptor antagonist, nor-binaltorphimine
nor-BNI; 1 mg/kg, i.p.)  were administered 90 min, 15 min  and
0 min  respectively, before oral administration of 500 mg/kg of
EMC. The nociceptive stimulus was injected 60 min after PEMC
dministration.
PLC proﬁle of PEMC at various wavelengths
The HPLC proﬁle of PEMC was established according to the
ethods described in detail for MEMC  by Mohd Sani et al.
2012). In addition, PEMC was also spiked with a list of ﬂavonoid-
ased compounds, namely pinostrobin, hesperetin, ﬂavanone,
′,5,7-trihydroxy ﬂavanone, 2,4,4′-trihydroxy chalcone, quercitrin,
ihydroquercitin, ﬁsetin, quercetin, rutin, quercitrin, naringenin,
ilibinin, and genistein, to determine their presence in the extract.
he HPLC analysis was carried out in the Laboratory of Phy-
omedicine, Medicinal Plants Division, Forest Research Institute of
alaysia (FRIM), Kepong, Malaysia.
tatistical analyses
The results are presented as mean ± standard error of mean
SEM). The one-way ANOVA test with Dunnett’s multiple compar-
son and two-way ANOVA with Bonferroni post hoc test were used
o analyze and compare the data. p < 0.05 was set as the limit of
igniﬁcance.
esult
ntinociceptive proﬁle of PEMC
Fig. 1 shows that orally administered PEMC produced a sig-
iﬁcant (p < 0.001) and dose-dependent antinociceptive effect in
ice subjected to the acetic acid-induced abdominal constriction
est. The percentage analgesia produced ranged between 26 and
0%, while the positive control treatment (100 mg/kg ASA, p.o.)
roduced an analgesic effect of 59.31%.
Fig. 2 shows the centrally and peripherally mediated antinoci-
eptive proﬁle of orally administered PEMC as indicated by the
ormalin test. The extract exerted signiﬁcant (p < 0.05) and dose-
ependent antinociceptive activity in both the early and late phases
f the assay. The antinociceptive activity, in both phases, was lower
han that of 5 mg/kg morphine.
The central antinociceptive proﬁle of PEMC, performed using
ot plate test, a thermal-induced nociception model was shown in
ig. 3. PEMC exerted signiﬁcant (p < 0.001) antinociceptive activity
nly by the 500 mg/kg which is the highest dose tested. However,
he antinociception induced by PEMC was again lower than that
nduced by 5 mg/kg morphine administered via i.p.  injection.pared to negative control treatment by one-way analysis of variance followed by
Dunnett’s post hoc test.
Motor coordination and sedative effects of PEMC
Effect of PEMC on motor coordination
In the rota rod test, all doses of PECM did not impair motor
coordination at 0.5, 1 and 2 h post-administration in contrast to
2.5 mg/kg diazepam, which caused a signiﬁcant (p < 0.05) decrease(100, 250, and 500 mg/kg, p.o.), acetylsalicylic acid (ASA, p.o.), or morphine (5 mg/kg,
p.o.),  60 min  before i.pl. injection of formalin. The asterisks denote the signiﬁcance
levels as compared to control, ***p < 0.001 by one-way ANOVA followed by Dunnett’s
post hoc test. ***Data differed signiﬁcantly (p < 0.05) when compared to the 10%
DMSO-treated group.
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Fig. 3. Antinociceptive proﬁle of PEMC assessed using the hot-plate test in mice. *p < 0.05 when compared with the control group at same the respective interval. Data are
the  mean ± SEM; n = 6 mice per group.
Table 1
Effect of PEMC on motor coordination assessed by the rota-rod test.
Treatment Dose (mg/kg) Time (s) on Rota-rod/210 sa
30 min  60 min 90 min
10% DMSO – 210.0 ± 0.0 207.18 ± 2.11 210.0 ± 0.0
Diazepam 3 41.15 ± 6.32a 28.18 ± 7.35a 56.92 ± 7.43a
PEMC
100 205.49 ± 4.26 204.75 ± 3.64 210.0 ± 0.0
250  202.35 ± 6.14 207.03 ± 2.08 206.47 ± 2.52
500  208.08 ± 1.12 205.87 ± 3.02 210.00 ± 0.00
Data are the mean ± SEM; n = 6 mice per group. The rats were pretreated with 10% DMSO (negative control), 2.5 mg/kg diazepam (i.p.) or PEMC (100, 250, and 500 mg/kg,
p.o.)  30 min  before subjection to the test.
a Signiﬁcantly differed at P < 0.05 when compared to the control group as assessed by the one-way ANOVA followed by Dunnett’s post hoc test.
Table 2
Effect of PEMC on mice sleeping activity assessed using the sodium pentobarbital-induced sleeping test.
Treatment Dose (mg/kg) Onset of sleep (min) Duration of sleep (min)
10% DMSO – 3.48 ± 0.41 41.12 ± 0.33
Diazepam 1 1.72 ± 0.28a 94.33 ± 0.66a
PEMC
100 3.08 ± 0.17 68.66 ± 0.47a
250 3.26 ± 0.39 71.66 ± 0.49a
500 2.98 ± 0.32 88.83 ± 0.55a
Data are the mean ± SEM; n = 6 mice per group.
a e respective interval as assessed by the one-way ANOVA followed by Dunnett’s post hoc
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Fig. 4. Effect of PEMC on capsaicin-induced paw licking test in rats. Each columnSigniﬁcantly differed at P < 0.05 when compared to the control group at the sam
est.
odium pentobarbital-induced sleeping time test
Administration of PEMC did not cause changes in neither the
atency sedation nor the sleeping time induced by sodium pento-
arbital suggesting that PEMC did not exert sedative effects at any
f the doses tested (Table 2).
ole of TRPV1, glutamatergic, B2 receptors and PKC pathway
The ability of PEMC to inhibit the vanilloid receptor-induced
ociceptive transmission is shown in Fig. 4. The 250 and 500 mg/kg
EMC signiﬁcantly (p < 0.001) attenuated the capsaicin-induced
aw licking test in a dose-dependent manner with the percentage
f analgesia recorded ranging between 30 and 64%, respectively.
he inhibition percentage of 63.52% produced by 500 mg/kg PEMC
as higher than the positive control capsazepine (59.72%).
Fig. 5 shows the antinociceptive proﬁle of PEMC against
lutamate-induced paw licking test. PEMC signiﬁcantly
p < 0.001) attenuated the nociceptive effect assessed using the
represents the mean ± SEM of six rats. The rats were pretreated with vehicle (con-
trol, 10% DMSO) or PEMC (100, 250, and 500 mg/kg, p.o.) 60 min  before injection
of  capsaicin (1.6 g/paw, 50 l, i.pl.). The asterisks denote the signiﬁcance levels as
compared to control, ***p < 0.001 by one-way ANOVA followed by Dunnett’s post
hoc  test.
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Fig. 7. The antinociceptive effect of PEMC against bradykinin-induced paw licking.
lutamate (10 mol/paw, 50 l, i.pl.). The asterisks denote the signiﬁcance levels as
ompared to control, ***p < 0.001 by one-way ANOVA followed by Dunnett’s post
oc  test.
lutamate-induced paw licking test in a dose-dependent manner.
he percentage of analgesia obtained from the administration of
00, 250 and 500 mg/kg PEMC ranging between 32 and 69%.
Fig. 6 shows that the oral administration of 250 and 500 mg/kg
EMC produced signiﬁcant (p < 0.001) inhibition of PMA-induced
ociception in rat. Interestingly, the 500 mg/kg PEMC exerted
lightly better antinociceptive activity compared to 100 mg/kg ASA
ndicated by the calculated percentage of analgesia (66.38% and
5.36% respectively).
As seen in Fig. 7, PEMC given orally exhibits signiﬁcant inhi-
ition in a dose-dependent manner on the nociception caused by
ntra-plantar injection of bradykinin in rat. The maximal inhibition
bserved was 53.92% for dose 500 mg/kg. Similar inhibitory effect
as observed for 100 mg/kg aspirin.
valuation of l-arginine/NO/cGMP pathway
Fig. 8a and b show the role of the abdominal constriction tests
ncorporating l-arginine, l-NAME and MB  to explore the role of the
-arginine/NO/cGMP pathway in the modulation of PEMC-induced
ntinociceptive activity. In Fig. 8a, pretreatment with 20 mg/kg l-
rginine did not produce any signiﬁcant effect when compared to
he negative control. Meanwhile, pre-treatment with 20 mg/kg l-
AME alone exerted a signiﬁcant antinociceptive effect. However,
he positive effect was diminished when l-NAME given in combina-
ion with l-arginine. In the groups treated with PEMC, pretreatment
ith l-NAME did not affect the extract antinociceptive activity,
hereas pretreatment with l-arginine signiﬁcantly reduced, but
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ig. 6. Effect of PEMC on nociception induced by phorbol 12-myristate 13-acetate
PMA) on rats. Each column represents the mean ± SEM time spent on paw-licking
ehavior of six animals. Animals were administered with vehicle (negative control),
EMC (100, 250, and 500 mg/kg, p.o.) or acetylsalicylic acid (ASA; 100 mg/kg, p.o.)
0  min  before injection of PMA  (50 ml  solution containing 0.05 mg PMA/paw) in the
ight hind paw. Numbers above bars indicate percentage of analgesia. ***p < .001
s  compared to the control group by one-way analysis of variance followed by
unnett’s post hoc test.Each column represents the mean ± S.E.M. of six rats. Vehicle (negative control;
10% DMSO, p.o.), PEMC (100, 250 and 500 mg/kg, p.o.) and acetylsalicylic acid (ASA:
100  mg/kg, p.o.). ***p < 0.001 when compared to control group.
did not completely inhibit, the antinociceptive effects of PEMC. Pre-
treatment with a combination of l-arginine and l-NAME also failed
to affect the intensity of PEMC antinociception.
Pretreatment with 20 mg/kg MB  alone (Fig. 8b) exerted
signiﬁcant (p < 0.05) antinociceptive activity and co-treatment
with 20 mg/kg l-arginine failed to reverse MB  antinociception.
Pre-treatment with MB  signiﬁcantly (p < 0.05) enhanced PEMC
antinociception while co-treatment with MB  and l-arginine failed
to affect the antinociceptive intensity of PEMC.
Involvement of potassium channels, non-opioid and opioid
receptors on PEMC-induced antinociception
Fig. 9 shows the involvement of potassium channels in the
modulation of PEMC-induced antinociceptive activity. Pretreat-
ment with glibenclamide (10 mg/kg, i.p.), Apamin (0.04 mg/kg, i.p.),
charybdotoxin (0.02 mg/kg, i.p.)  and tetraethylammonium chloride
(4 mg/kg, i.p.), signiﬁcantly (p < 0.01) reversed the antinociceptive
activity of PEMC (500 mg/kg) when assessed using acetic acid-
induced abdominal writhing test.
The effect of antinociceptive activity of PEMC was  signiﬁ-
cantly (p < 0.05) reversed following intraperitoneal administra-
tion of several receptor antagonists (Fig. 10) namely caffeine
(3 mg/kg), atropine (10 mg/kg), yohimbine (0.15 mg/kg), haloperi-
dol (0.2 mg/kg), pindolol (0.2 mg/kg), or naloxone, naltrindole,
nor-binaltorphimine and -funaltrexamine (Fig. 11).
HPLC proﬁle of PEMC
The HPLC analysis of PEMC was measured at various different
wavelengths (e.g. 210, 254, 280, 300, 330 and 366 nm and the best
separation was  obtained at 300 nm (Fig. 12a). Four major peaks
were separated at these wavelengths, which were labeled as P1
(RT 13.772 min), P2 (RT 20.171 min), P3 (RT 21.592 min), and P4 (RT
28.144 min). Further analysis demonstrated that these four peaks
showed max values in the region of 211.9–272.0, 234.3–308.8,
240.1–270.8, 241.3–292.2 nm,  respectively (Fig. 12b), suggesting,
in part, the presence of ﬂavonoid-based compounds. Compari-
son between chromatogram of PEMC and chromatogram of the
standard compounds demonstrated the presence of pinostrobin
and ﬂavanone (Fig. 12c).
DiscussionThe present study was  the continuation of previous studies by
Mohd Sani et al. (2012) and Zakaria et al. (2014a,b) on antinocicep-
tive and mechanism of actions proﬁle for methanolic crude extract
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ntinociception as assessed by acetic acid-induced abdominal constriction test. The
roups; ap < 0.001 when compared with control group, bp < 0.05 when compared w
f M.  calabura (MEMC). Recent laboratory study conducted focus-
ng on the antinociceptive potential of partition extracted from
he MEMC,  where the crude extract partitioned using three sol-
ent with different polarity namely petroleum ether, ethyl acetate
nd aqueous using the method described above. Using acetic acid-
nduced abdominal writhing test to screen for antinociceptive
ctivity, petroleum ether partition produced signiﬁcantly better
ctivity (data not shown). Hence, the PEMC selected to be further
ested for its antinociceptive properties as well as the mechanism
f actions.
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ig. 9. Effect of PEMC on nociception in the acetic acid-induced abdominal constriction te
epresents the mean ± SEM number of constrictions observed in six animals. Vehicle (10
APA:  0.04 mg/kg, i.p.), tetraethylammonium chloride (TEA: 0.01 mg/kg, i.p.) The asterisks, *
ontrol  group. Comparisons between groups were made by one-way analysis of varianceoc test. (B) Effects of l-arginine, methylene blue, and their combination on PEMC
rs and symbol above the columns represent signiﬁcance levels between compared
-treated group, #p < 0.05 when compared between selected group.
Our data shown the PEMC attenuated the nociceptive response
induced by chemical and thermal stimuli, suggesting that the com-
pound exerts peripheral and central antinociceptive activities. Its
ability to inﬂuence both peripheral and central nociception was
further conﬁrmed by our observation of its antinociceptive effects
in both phases of the formalin test. Overall, these observations
suggest that the antinociceptive activity of PEMC resembles that
of opioid analgesics, such as morphine. Moreover, the ability of
PEMC to attenuate nociception in both the abdominal constric-
tion and hot plate tests suggests that the compound is effective
dH2O APAGLIB CHAR TEA
PEMC
∗∗
∗
∗∗
st in mice following pretreatment with potassium channels inhibitors. Each column
% DMSO, p.o.), PEMC (500 mg/kg, p.o.), glibenclamide (GLIB: 10 mg/kg, i.p.), apamin
p < 0.05 and **p < 0.01, denote the signiﬁcance levels as compared to their respective
 followed by Dunnett’s post hoc test.
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V:  10% DMSO, p.o.), PEMC (PE: 500 mg/kg, p.o.), atropine (A: 10 mg/kg, i.p.) haloper
.15  mg/kg, i.p.). ap < 0.001 signiﬁcantly different when compared to vehicle-treated
ith both inﬂammatory-induced and non-inﬂammatory-induced
ociception, respectively (Zakaria et al., 2007a,b), which also sup-
orted by our data from the formalin-induced paw licking test
here both phases, the early (neurogenic) and late (inﬂammatory)
hase, attenuated by PEMC treatment.
The acetic acid-induced abdominal constriction test, described
s a typical model for inﬂammatory pain, has long been widely
sed as a tool to screen for analgesic or anti-inﬂammatory prop-
rties of new agents (Collier et al., 1968; Vongtau et al., 2004).
he acetic acid-induced abdominal constriction test reﬂects the
nﬂammatory-mediated nociceptive response (Mohd Sani et al.,
012) where the injected acetic acid into the peritoneal cavity
ncreases the level of cyclooxygenase (COX) and lipooxygenase
LOX) in the peritoneal ﬂuid and indirectly leads to the release
f endogenous mediators such as prostaglandin E2 (PGE2), PGF2,
erotonin, histamine, cytokines, and eicosanoids. These endoge-
ous mediators, in turn, excite the peripheral nociceptive neurons
ithin the peritoneal cavity that are sensitive to non-steroidal anti-
nﬂammatory drugs (NSAID) (Ikeda et al., 2001). The increased
evels of PGE2 due to prolong irritation of peritoneal cavity lead
o enhanced capillary permeability (Deraedt et al., 1980; Vogel and
ogel, 1997) as well as the release of glutamate and substance P
rom peripheral afferent ﬁber (Millan, 1999), indicating the stimu-
ation of peripheral nociceptive mechanisms. The ability of PEMC
o inhibit acetic acid-induced nociception suggests that the com-
ound attenuates the levels of peripheral COX and LOX, which
ndirectly decreases PGE2 synthesis and obstructs the transduc-
ion of pain in primary afferent nociceptors. However, the acetic
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ig. 11. Analysis of opioid receptor subtypes involvement in PEMC-induced antinocicept
EMC  (500 mg/kg, p.o.), naloxone (NLX: 5 mg/kg, i.p.), naltrindole (NALT: 1 mg/kg, i.p.), -f
nd  acetylsalicylic acid (ASA: 100 mg/kg, p.o.). **p  < 0.01 and ***p < 0.001 when comparedtinociception against acetic acid-induced abdominal writhing test in mice. Vehicle
: 20 mg/kg, i.p.), pindolol (P: 1 mg/kg, i.p.), caffeine (C: 3 mg/kg, i.p.), yohimbine (Y:
p; bp < 0.001 signiﬁcantly different when compared to PEMC-treated group.
acid-induced abdominal construction test is not speciﬁc, thus fur-
ther studies using other nociceptive models, namely the hot plate
and formalin tests are required to determine whether the antinoci-
ceptive effects of PEMC are centrally or peripherally mediated.
The hot plate test, predominantly a spinal reﬂex test that
involves activation of the supraspinal nociceptive processing, has
been applied in various researches to show that only the anal-
gesic acting centrally, but not peripherally, have an effect on this
test (Chen et al., 1995; Le Bars et al., 2001; Hosseinzadeh and
Younesi, 2002; Giglio et al., 2006). The ability of PEMC to inhibit
both the early and late phases of the formalin test in the present
study conﬁrmed the extract’s ability to exert centrally and periph-
erally mediated antinociceptive effects (Mohd Sani et al., 2012;
Mohamad Yusof et al., 2013). The early phase, classiﬁed as a neuro-
genic pain, is an acute reaction, lasted for 5 min which immediately
occur after the injection of formalin where it directly activate the
nociceptors. The late phase, appears between 15 and 30 min fol-
lowing formalin injection, is classiﬁed as an inﬂammatory pain as
it is caused by inﬂammatory mediators released such as histamine,
serotonin, bradykinin and PGE2 (Verma et al., 2005). Our results
in the present study indicate that PEMC possesses mild centrally
mediated antinociceptive characteristics as seen in both the hot
plate test and early phase of formalin test.
Over the past decade, tremendous research being devoted in
developing the best medication for pain reliever, and extensive
studies has been perform to explore their precise mechanism of
action in order to understand and limit any unwanted side effect.
However, the neuronal basis of pain transmission and modulation
PEMC + NALTNALT+ β-FNA ASAPEMC + nor-
BNI
nor-BNI
∗∗∗
∗
∗
ion against acetic acid-induced writhing test in mice. Control (C: 10% DMSO, p.o.),
unaltrexamine (-FNA: 10 mg/kg, i.p.), nor-binaltorphimine (nor-BNI: 1 mg/kg, i.p.)
 to the group treated only with PEMC.
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Fig. 12. (A) The HPLC proﬁle of PEMC at different wavelengths (i.e. 254, 300 and 366 nm). Several major peaks were detected at the retention time (RT) of 13.77, 20.14,
21.98,  26.08 and 29.25 s at the wavelength of 330 nm. (B) The HPLC proﬁle of PEMC at different wavelengths (i.e. 210, 254, 280, 300. 330 and 366 nm)  supported by the
UV  spectra analysis of PEMC. The UV spectra demonstrated the presence of four major peaks labeled as P1 (RT 13.772 min), P2 (RT 20.171 min), P3 (RT 21.592 min), and P4
(RT 28.144 min), which were observed at their respective max at the region of 211.9–272.0, 234.3–308.8, 240.1–270.8, 241.3–292.2 nm,  respectively, suggesting, in part the
presence  of ﬂavonoid-based compounds. (C) Comparison of the HPLC proﬁle of PEMC against several pure ﬂavonoids at the wavelength of 366 nm.  Only comparison with
pinostrobin and ﬂavanone demonstrated matching HPLC proﬁle to that of the extract.
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ember 1.
s still not completely understood. Numerous chemicals and factors
uch as opioids, substance P, glutamate, nitric oxide, serotonin, and
ther inﬂammatory mediators, has been documented to engaged
n the activation of the PNS and CNS nociceptive pathways (Mohd
ani et al., 2014). The existence description of these modulatory
echanisms such as the role of vanilloid receptors, glutamater-
ic system, opioid and non-opioid receptors, nitric oxide, PKC as
ell as K+ channels pathways, have beneﬁted and provide guidance
or researchers in the development of new analgesic candidates
Rodella et al., 2010).
Our previous study (Mohd Sani et al., 2012; Zakaria et al.,
014a,b) using the crude methanol extract of M. calabura (MEMC)
evealed the participation of most the modulatory mechanisms.
n the present study, we employed the same approach to explore
he possible mechanisms of action responsible for the observed
ntinociceptive activity of PEMC. Based on our ﬁndings, PEMC; (1)
ttenuate the nociception induced by capsaicin indicating possible
nvolvement of vanilloid receptors, (2) inhibit glutamate-induced
ociception which in turn inhibit the release of NO and NO-related
ubstance (Beirith et al., 2002), (3) signiﬁcantly inhibit PMA-
nduced nociception suggesting its involvement in PKC-activated
hosphorylation of vanilloid receptor pathway (Vellani et al., 2001),
4) inhibit bradykinin-induced nociception showing its ability to
lock B2 receptor from being activated, (5) affected by l-arginine,
ut not l-NAME and MB,  suggesting PEMC antinociception did
ot involve modulation via the l-arginine/NO/cGMP pathway, (6)
nvolved in the activation of ATP-sensitive K+ channels, small
onductance Ca2+-activated K+ channels and non-selective voltage-
ependant K+ channels, but not large conductance Ca2+-activated
+ channels, (7) play signiﬁcant role in antinociception modulated
y adenosinergic, 2-noradrenergic, cholinergic and -adrenergic
eceptors, (8) involved in the activation of opioid receptor subtypes
s PEMC antinociceptive effect was signiﬁcantly reduced by the
retreatment of ,  and  opioid receptor subtype inhibitors.
Our ﬁndings, apart from the possible participation of choliner-
ic receptor and inability of PEMC to activate large conductance
a2+-activated K+ channels, were in line with our results obtained
rom the crude methanol extract of M.  calabura. The involvement of
holinergic receptor seen in PEMC-induced antinociceptive might
robably due to higher purity of the expressed bioactive com-
ounds extracted from the crude extract.; NO: nitric oxide; TRPV1: transient receptor potential cation channel subfamily V
Earlier studies implied that the depression of CNS and the effect
of nonspeciﬁc muscle relaxation can diminish the response of
motor coordination and, accordingly, may  nullify the antinocicep-
tive results (Quintans-Júnior et al., 2010). Interestingly, the present
ﬁndings demonstrated that PEMC-treated (100, 250 and 500 mg/kg,
orally) mice exerted no performance alterations in the rota-rod-
and pentobarbital-induced sleeping-test indicating that PEMC did
not interfere in the mice anxiety behavior or in the motor function,
when compared to the control group. In contrast, diazepam induced
anxiety reduction demonstrated by an increase in the number of
visits and time spent in the open arms and by an increase in the total
number of entries. Overall, these ﬁndings suggested that there is no
alteration in motor coordination among the treated animals, there-
fore, eliminating a nonspeciﬁc muscle relaxation as well as sedative
effects of PEMC at the doses used. These results suggest that the
antinociceptive effect of PEMC is not related to sedative effect or to
alteration in motor function (de Vasconcelos et al., 2011).
The phytochemical screening of PEMC was  in accordance
with the phytoconstituents found in the crude extract (MEMC)
as previously reported by Zakaria et al. (2014a,b). Phytochemi-
cal constituents of PEMC include ﬂavonoids, triterpenes, tannins
and steroids, and some of these compounds have been reported
to exert antinociceptive activity (Starec et al., 1988; Beirith
et al., 1999; Karumi et al., 2003; Musa et al., 2009). Moreover,
ﬂavonoids like pinostrobin have been identiﬁed from the leaves
of M. calabura (Su et al., 2003; Chen et al., 2005) and also
detected in PEMC via the qualitative HPLC method. Despite vari-
ous reports on the pharmacological potential of pinostrobin, none
of those reports were related to the antinociceptive activity. How-
ever, pinostrobin has been reported to exert anti-inﬂammatory
activity (Tuchinda et al., 2002; Patel and Bhutani, 2014) and
might, therefore, supported the PEMC antinociceptive activity.
Moreover, recently published report by Mohamad Yusof et al.
(2013) revealed that the antinociceptive activity of PEMC assessed
using only the formalin test could be due to the presence of
several ﬂavonoid-based bioactive compounds, namely 5-hydroxy-
3,7,8-trimethoxyﬂavone, 3,7-dimethoxy-5-hydroyﬂavone, 2′,4′-
′dihydroxy-3 -methoxychalcone, and calaburone. These com-
pounds have been shown to exhibit antinociceptive activity when
given separately and, therefore, they are suggested to act synergis-
tically to exert the antinociceptive effect.
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Further analysis of the identiﬁed peaks based on the recorded
V spectra revealed that the four peaks falls between the max
f 210 and 310 nm suggesting the presence of ﬂavonoid-based
ioactive compounds as reported by Aznam et al. (2012). There
re ﬁve major subgroups of ﬂavonoids namely ﬂavones, ﬂavonols,
avanonols, ﬂavanones and dihydroﬂavonols (Tsimogiannis et al.,
007). The presence of ﬂavanones-based bioactive compounds, in
articular, can be suggested based on the recorded UV–Vis spectra
btained for each of the peak (Aznam et al., 2012). According to
znam et al. (2012), several ﬂavonoids that have methoxyl and
ydroxyl groups, detected at the UV spectra that range between
10 and 290, have been isolated from fractions of methanol extract
f Kaempferia rotunda. Recent studies by Mohamad Yusof et al.
2013) tend to support the presence of ﬂavanones or methoxyl-
nd hydroxyl-contained ﬂavonoids in PEMC as the authors have
uccessfully isolated several antinociceptive-bearing ﬂavanones,
amely 5-hydroxy-3,7,8-trimethoxyﬂavone, 3,7-dimethoxy-
-hydroyﬂavone, 2′,4′-dihydroxy-3′-methoxychalcone, and
-hydroxy-6-methoxyﬂavone (calaburone).
It is reasonable to conclude from our ﬁndings in the present
tudy that the antinociceptive properties of PEMC occur via interac-
ion of a variety of physiological pathways within the PNS and CNS.
EMC appears to act as an agonist for potassium channels, opioid,
holinergic, adenosinergic, adrenergic, and serotonergic receptors,
hile at the same time inhibiting the PKC, vanilloid receptors and
lutamatergic system. Fig. 13 represents a model of the mecha-
isms of PEMC’s antinociceptive action based on these ﬁndings.
hese activities could be due to the synergistic effect of ﬂavonoids,
riterpenes, tannins and steroids. The knowledge gained from such
tudies in the present and future will be useful for the design or dis-
overy of new chemical entities that exhibit similar antinociceptive
ctivity.
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